Caisse de depot et placement du Quebec Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Caisse de dépôt et placement du Québec acquired 250,608 Regeneron shares worth approximately $156.3 million, giving it a 0.24% stake. Institutional investors collectively own 83.31% of the company.
• Regeneron reported strong quarterly results, with EPS of $14.29 beating estimates of $10.16 and revenue of $4.29 billion exceeding expectations. Revenue increased 16.7% year over year.
• REGN recently traded at $814.79, while analysts maintain a “Moderate Buy” consensus and an average price target of $800.36; the company also declared a quarterly dividend of $0.94 per share. Separately, securities litigation allegations tied to the Fianlimab-Libtayo melanoma study add uncertainty for investors.

Caisse de depot et placement du Quebec acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 250,608 shares of the biopharmaceutical company's stock, valued at approximately $156,264,000. Caisse de depot et placement du Quebec owned about 0.24% of Regeneron Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of REGN. SHP Wealth Management purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $26,000. Western Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth about $26,000. Titan Wealth CI Ltd bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $29,000. Mowery & Schoenfeld Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $29,000. Finally, Trust Co. of Vermont bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $29,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $814.79 on Thursday. The company has a market cap of $83.89 billion, a P/E ratio of 20.14, a price-to-earnings-growth ratio of 1.42 and a beta of 0.22. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm's 50-day moving average price is $709.88 and its 200-day moving average price is $717.69. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals's revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the business earned $12.81 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,400 shares of company stock worth $1,090,030. Company insiders own 6.97% of the company's stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Despite the setback, Wall Street remains generally constructive on Regeneron’s long-term growth prospects, and the shares have outperformed the broader S&P 500 over the past year. The company’s latest reported quarter also showed strong execution, with revenue up 16.7% year over year and EPS substantially above consensus estimates. Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?
• Neutral Sentiment: A reported August short-interest update showed zero shares sold short, but the figures appear incomplete or erroneous because the reported change was listed as “NaN.” It therefore provides little reliable information about current trading sentiment.
• Negative Sentiment: Several law firms announced or promoted a securities class action alleging that Regeneron misled investors about the viability and prospects of the Phase 3 Fianlimab-Libtayo melanoma study, including by emphasizing earlier-stage results and practice-changing expectations. The allegations have not been proven, but the litigation adds reputational, financial, and uncertainty-related overhang. Investors who purchased shares between August 1, 2025, and May 15, 2026, are being reminded of a September 14, 2026, deadline to seek lead-plaintiff status. Regeneron Investors: September 14, 2026 Lead Plaintiff Deadline

Analysts Set New Price Targets

A number of research firms have recently weighed in on REGN. Piper Sandler reduced their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating on the stock in a report on Thursday, July 9th. Benchmark upgraded Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price target for the company in a research report on Tuesday, July 7th. Royal Bank Of Canada boosted their target price on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a "sector perform" rating in a research report on Friday, July 31st. Wells Fargo & Company boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a research note on Friday, July 31st. Finally, Citigroup increased their price objective on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a "neutral" rating in a research note on Monday, August 3rd. Fifteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $800.36.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source